INTERNATIONAL JOURNAL OF ADVANCE RESEARCH, IDEAS AND INNOVATIONS IN TECHNOLOGY

ISSN: 2454-132X
Impact factor: 6.078
(Volume 6, Issue 2)
Available online at: www.ijariit.com

Synthesis and anti-inflammatory activity of some 2-(3'-aminesubstituted)-7- hydroxyl-4H-1-benzopyran-4-one derivatives

Awinash Chavan
avichavan4741@gmail.com
Raosaheb Patil Danve College of Pharmacy, Badnapur, Maharashtra

Prafulla Sabale
prafullasabale@gmail.com
R. T. M. Nagpur University, Nagpur, Maharashtra

ABSTRACT

A series of 2-(3'-aminesubstituted)-7- hydroxyl-4H-1-benzopyran-4-one amine derivatives has been synthesized by condensation of 2,4-Dihydroxyacetophene (1.40 ml) and 3-Chlorobenzaldehyde (0.01 mole) through Claisen-Schmidt condensation reaction. Novel flavone derivatives were access for anti-inflammatory activity by using carrageenan induced rat paw edema method. Among the synthesized compounds (t, v, w, k) shows good anti-inflammatory activity comparable to reference drug (Celecoxib).

Keywords— *Synthetic Flavone, Claisen-Schmidt Condensation Reaction, Anti-inflammatory, Celecoxib*

1. INTRODUCTION

Flavonoids based on the backbone of 2-phenyl-*4H*-chromen-4-one (2-phenyl-1-benzopyran-4-one). The molecular formula of flavone molecule is $C_{15}H_{10}O_2$. It has three-ring skeletons, C6-C3-C6, and the rings are referred to as A, C, and B rings, respectively. They are found in seeds, citrus fruits, olive oil, tea and red wine, vegetables, nuts, stems and flowers, honey and are commonly consumed with the human diet. 2-(3'-aminesubstituted)-7- hydroxyl-4*H*-1-benzopyran-4-one derivatives these are non-steroidal anti-inflammatory drugs (NSAIDs) exhibit their effect by inhibiting COX enzymes and by blocking the synthesis of prostaglandins. In a literature, revealed that, flavone shows good to moderate anti-inflammatory activity. It is also observed that the flavone moiety should possess following characteristic pharmacophore pattern which is essential for binding to cyclooxygenase enzyme and they're by its inhibition. Flavone possess following pharmacophoric pattern (Figure 1).

(a) The ligand should possess suitably positioned hetero atom, which strongly interact with heme iron.
(b) The ligand should have a hydrophobic spacer moiety between heme coordinating group and hydrogen bond acceptor moiety.
(c) Cyclooxygenase inhibitors need a chemical group that is able to accept H-bond from Serine 478 present in active site.



Fig. 1: Pharmacophore Pattern of Cyclooxygenase Inhibitors

On the basis of literature and Pharmacophore pattern of non-steroidal aromatase inhibitors, the aim of present work is, to synthesize novel flavone derivatives, with aliphatic and aromatic amines for anti-inflammatory screening i.e. as a fundamental hetero-aliphatic/aromatic system with modification.

2. RESULT AND DISCUSSION

Molecular docking of flavones studies on COX-2 enzyme

Molecular docking studies of all proposed flavones derivatives were carried using maestro 11.5 schrodinger software. Glide score is the function, designed to calculate the free energy of binding for a protein-ligand complex.

$$XPGlide\ score = E_{coul} + E_{vdw} + E_{bind} + E_{penalty}$$

Where, $E_{bind} = E_{hyd\text{-}enclosure} + E_{h\text{-}bond\ modif} + E_{h\text{-}bond\_cc\_modif} + E_{Pi\ interaction} + E_{h\text{-}bond\ pair}$

$E_{penalty} = E_{disolve} + E_{ligand\ strain}$

Hydrogen bonds provides stability to the protein-ligand complex, that means more the number of hydrogen bonding with protein, more will be the fitting of ligand molecule in the binding pocket and hence stay more bound or docked with the receptor. These provides stability to the complex. Total 8 molecules of flavones were designed and docked on COX-2 enzyme. Out of these, three molecules with good hydrogen bond interactions and glide score as compared to standard celecoxib are selected. Which includes **(t,v,w,k)** The Glide score (G-score) and the number of H bonds of all docked ligands and the standard SC-558, Celecoxib are shown in Table 4.

Table 1: Docking Score, Glide score (G-score) and number of H-bonds for the flavones and Celecoxib

Compound Code	Docking Score (Kcal/mole)	Glide score (Kcal/mole)	H-bonds
a	-8.253	-8.253	0
b	-9.077	-9.089	2
c	-8.060	-8.060	0
k	-8.331	-8.443	1
l	-8.574	-8.594	2
t	**-10.916**	**-10.928**	**3**
v	**-11.086**	**-11.099**	**3**
w	**-10.525**	**-10.538**	**3**
Celecoxib	**-11.197**	**-11.198**	**3**

Compound **t, v, w** possess 3 hydrogen bonding and having glide score of **-10.928, -11.099** and **-10.538** respectively, Compound **k** has single hydrogen bonding and quiet good dock score. **a** and **c** have no hydrogen bonding with COX-2 enzyme. It is reported in the literature that good bonding with Tyr355, Arg120, Leu531, Ser353, Ser530 and Tyr 385 is required for good affinity and also for good fitting of the compounds when docked into the enzyme pocket. Therefore, from the docking result compound **t, v, w**, **k** are considered for the synthesis which may shows good anti-inflammatory activity. Fig. 12-14 shows hydrogen bonding of (**v)** and standard **Celecoxib.**

Table 2: Amino acids of 1CX2 enzyme making H-bonding interactions, π-π and π-cation interactions with Celecoxib and novel flavones

Sr. No.	Compound	Name of amino acids involved in interaction with ligands
1.	Celecoxib	SER 353, LEU 352, ARG 513
2.	t	TYR 355, MET 522
3.	v	MET 522, TYR 385, TYR 355
4.	w	MET 522, TYR 385, PHE 518

From above table 6 it is clear that flavones showed good hydrogen bonding, π-π stacking and π-cation bonding with COX-2 enzyme. The following figure 2, 3,4 5 shows docked molecules in binding pocket of COX-2 enzyme.



Fig. 2: Ribbon structure of COX-2 enzyme with Celecoxib



Fig. 3: Ribbon structure of COX-2 enzyme with (v).



Fig. 4: Amino acids of COX-2 enzyme showing hydrogen contacts with Celecoxib



Fig. 5: Amino acids of COX-2 enzyme showing hydrogen contacts with (v)

3. SYNTHETIC WORK

In the present work, synthesis of novel flavone derivatives was carried out by reacting 2, 4-dihydroxyacetophenone with 3-chlorobenzakdehyde in basic medium in microwave for 3 min at level 5 to gives 3-(3'-chlorophenyl)-1-(2,4-dihydroxyphenyl)-prop-2-en-1-one shown in step: I. Further it is, cyclized in microwave for 2-3 min at level 5 to in the presence of DMSO/I_2 or H_2O_2/ NaOH to form 2-(3'-chlorophenyl)-7- hydroxyl-4*H*-1-benzopyran-4-one step: II. Finally synthesis of all proposed novel flavone derivatives was carried out by adding a aliphatic or aromatic amines to a 2-(3'-chlorophenyl)-7- hydroxyl-4*H*-1-benzopyran-4-one in pyridine, then mixture was irradiated in microwave for 2-3 min at level 5 to achieve target derivatives step: III. Crude product was then crystallized from methanol (Scheme:1).



Scheme 1: Synthetic scheme

Table 3: Derivatives of novel flavonoids

Sr. No.	Compound	-R/Ar	Sr. No.	Compound	-R/Ar
1	**A**	Methylamino	5	**l**	Ethylmethylamino
2	**B**	Ethylamino	6	**t**	*p*-Methylaniline, ,
3	**C**	Propylamino	7	**v**	*p*-Chloroaniline
4	**K**	Diethylamino	8	**w**	*p*-Nitroaniline

Table 4: Characterization data for 2-(3'-aminesubstituted)-7- hydroxyl-4*H*-1-benzopyran-4-one derivatives

Sr. No.	Code	Molecular Formula	Mol. Weight (g/mol)	Yield %	Melting Point (°C)	Rf-Value	U.V. λ_{max} (nm)
1	**a**	$C_{16}H_{13}NO_3$	267	63.12	178-180	0.6	241.60
2	**b**	$C_{17}H_{14}NO_3$	280	57.00	184-185	0.82	309.20
3	**c**	$C_{18}H_{17}NO_3$	295	57.86	187-190	0.84	297.00
4	**k**	$C_{19}H_{19}NO_3$	309	66.21	179-182	0.62	298.00
5	**l**	$C_{18}H_{17}NO_3$	295	59.09	181-183	0.47	319.00
6	**t**	$C_{22}H_{18}NO_3$	365	72.25	190-195	0.72	340.00
7	**v**	$C_{21}H_{15}NO_3CI$	375	69.24	192-196	0.82	290.00
8	**w**	$C_{21}H_{15}N_2O_5$	344	70.16	190-194	0.68	318.00

Table 5: Anti-inflammatory activity obtained by carrageenan induced rat paw edema method & Comparative study of inhibition (%I) for anti-inflammatory activity by carrageenan induced rat paw edema method

Sr. No.	Groups	Mean of Paw Volume (mL)				±SEM				% Inhibition of Paw edema			
		0 h	1 h	2 h	3 h	0 h	1 h	2 h	3 h	0 h	1 h	2 h	3 h
1	**Control**	0.51	0.57	0.56	0.55	0.087	0.098	0.095	0.098	--	--	--	--
2	**A**	0.56	0.47	0.46	0.45	0.098	0.142	0.096	0.122	--	17.55	17.86	18.19
3	**B**	0.56	0.47	0.46	0.45	0.098	0.142	0.096	0.122	--	16.20	16.80	17.02
4	**C**	0.57	0.48	0.46	0.46	0.098	0.102	0.096	0.096	--	16.79	16.04	17.37

5	**K**	0.57	0.43	0.38	0.32	0.080	0.128	0.124	0.107	--	23.70	33.14	44.03
6	**L**	0.51	0.43	0.46	0.4	0.102	0.143	0.149	0.145	--	24.57	25	27.28
7	**T**	0.57	0.43	0.38	0.3	0.098	0.128	0.128	0.109	--	30.70	39.14	40.03
8	**V**	0.57	0.43	0.42	0.41	0.098	0.143	0.149	0.160	--	21.46	24	24.46
9	**W**	0.51	0.36	0.3	0.2	0.102	0.092	0.088	0.052	--	43.26	43.75	45.08
10	**Celecoxib**	0.54	0.38	0.38	0.27	0.096	0.104	0.104	0.087	--	33..34	32.15	45.91

4. CONCLUSION

From present work it is prove that novel series of 2-(3ˀ-aminesubstituted)-7- hydroxyl-4*H*-1-benzopyran-4-one derivatives has been synthesized, physical characteristics followed by the anti-inflammatory screening occurs. Derivatives **(t, v, w, k)** shows the good anti-inflammatory activity when compared against vehicle treated control and standard Celecoxib.

5. ACKNOWLEDGMENT

Authors gratefully acknowledge to Dr. Raghu Rangaswamy, Vice President SchrödingerInc. for providing me one month free trial license to do my project work. Authors are also thankful to University Department of Pharmaceutical Sciences, Rashtrasant Tukadoji Maharaj Nagpur University, Nagpur and Dr. Prafulla M. Sabale Director of Board of Examination and Evaluation
Rashtrasant Tukadoji Maharaj Nagpur University, Nagpur for providing necessary facilities.

6. REFERENCES

[1] Alvaewz-BJ, Barluenga J. Heterocyclic compounds: An introduction, Modern Heterocyclic Chemistry. First Edition, 2011.
[2] Sourav D, NiranjanBabu M, Suneel Babu T, BhavyaSree R, Sai Kiran A, Sunil K. A review article on importance of heterocyclic compounds. Mintage Journal of Pharmaceutical & Medical Sciences. 2016; 18-27.
[3] Abbas AM. A review: Biological importance of heterocyclic compounds. Der Pharma Chem. 2017; 141-147.
[4] Arora V, Lamba HS, Deepak W. Importance of heterocyclic chemistry: a review. Int J Pharm Sci Res. 2012; 3: 2947-2954.
[5] Gupta R. Biological significance of nitrogen containing heterocyclic compounds – a mini review. Int J Comput Appl. 18-23.
[6] Gupta M. Heterocyclic compounds and their biological significance: A Review. Int J Phys Chem Math Sci. 2015; 4.
[7] Simon Pearce. The Importance of Heterocyclic Compounds in Anti-Cancer Drug Design: 2017.
[8] Pedro M, Jesus J, Sofia S, Luis R, Catarina R, Pedro V, Alexandra R. Heterocyclic anticancer compounds: recent advances and the paradigm shift towards the use of nanomedicine's tool box. Molecules. 2015; 20: 16852-16891.
[9] Haider S. Heterocycles, back bone of drug design. J Phytochemistry Bio Chem. 2017; 1: 1.
[10] Prof. (Dr.) Ciddi Veeresham. Natural products derived from plants as a source of drugs. J Adv Pharm Technol Res. 2012; 3: (4), 200–201.
[11] Hughes JP, Rees S, Kalindjian SB, Philpott KL. Principles of early drug discovery. Br J Pharmacol. 2011; 162: 1239-1249.
[12] Graham L. Patrick. An introduction to medicinal chemistry. Third edition. Oxford university press. 2006; 161-162.
[13] Kumar N, Hendriks BS, Kevin A, Graaf D, Lauffenburger DA. Applying computational modelling to drug discovery and development. Drug Discov Today. 2006; 11: (17), 806-811.
[14] Surabhi, Singh BK. Journal of Drug Delivery & Therapeutics. 2018; 8: (5), 504-509.
[15] Pranita PK, Madhavi MM, Rishikesh VA, Rajesh JO, Sandip SK. Computer-aided drug design: an innovative tool for modeling. Int J Med Chem. 2012; 2:139-148.
[16] Van J, Drie H. Computer-aided drug design: the next 20 years. J Comput Aided Mol Des. 2007; 21: (10-11), 591-601.
[17] Sliwoski G, Kthiwale S, Meiler J, Lowe. Pharmacological Reviews. 2013; 66: (1), 334-395.
[18] Vijayakrishnan R. Structure-based drug design and modern medicine. J Postgrad Med. 2009; 55: (4), 301-304.
[19] Talele TT, Khedkar SA, Rigby AC. Successful applications of computer aided drug discovery: moving drugs from concept to the clinic. Curr Top Med Chem. 2010; 1: 127-141.
[20] Gradman AH, Schmieder RE, Lins RL, Nussberger J, Chiang Y, Bedigian MP. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation. 2005; 111: (8), 1012-1018.
[21] Singh J, Chuaqui CE, Boriack-Sjodin PA, Lee WC, Pontz T, Corbley MJ, Cheung HK, Arduini RM, Mead JN, Newman MN, Papadatos JL, Bowes S, Josiah S, Ling LE. Successful shape-based virtual screening: The discovery of a potent inhibitor of the type I TGF beta receptor kinase (TbetaRI). Bioorg Med Chem Lett. 2003; 13: (24), 4355-4359.
[22] Ripphausen P, Nisius B, Peltason L, Bajorath J, Vadis Q. Virtual Screening? A comprehensive survey of prospective applications. J Med Chem. 2010; 53: 8461-8467.

